Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia

Overview

30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.

Full Title of Study: “Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: Double

Detailed Description

all participants will be administered panss, sans, esrs, calgary, progesterom, sexual functioning scale, ham-a, covy, hamilton depression scale, and cgi and cgi improved rating on the first visit, as well as blood tests, ecg and weight. they will then be tested using a computer cognitive test (cogscan test) that lasts about 45 minutes. next, they will be given either a two week dose of placebo or treatment (2 mg * 2 daily for first week, then 4 mg. day, 2 mg. night for the second week). after two weeks they the dose is increased to 4 mg. * 2 daily. at four weeks all tests are readministered, as well as at six weeks. the study is concluded at 6 weeks, following a readministration of tests. physical examination is also administered at the conclusion.

Interventions

  • Drug: reboxetine adjuvant therapy

Clinical Trial Outcome Measures

Primary Measures

  • sans, panss, hamilton, ham-a, calgary, physical examination, cogscan test

Secondary Measures

  • esrs, progesterom, sexual functioning, covy, cgi, cgi improved

Participating in This Clinical Trial

Inclusion Criteria

  • schizophrenia all types – 18> Exclusion Criteria:

  • uti – >65 – non organic state – no depression treatment

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Abarbanel Mental Health Center
  • Overall Official(s)
    • stanislav baranchik, md, Principal Investigator, abarbanel mhc
  • Overall Contact(s)
    • stanislav baranchik, md, 972-3-5552625

References

Schutz G, Berk M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol. 2001 Sep;16(5):275-8. doi: 10.1097/00004850-200109000-00004.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.